ホーム › 肝臓がん(肝細胞がん) › マサチューセッツ州
マサチューセッツ州における肝臓がん(肝細胞がん)の臨床試験
マサチューセッツ州内の拠点で、肝臓がん(肝細胞がん)に関する19件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト(英語)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483National Liver Cancer Screening Trial
- Massachusetts General Hospital, Boston
被験者募集中第4相
18歳〜85歳 · 全性別 · 2026/09/25更新 · NCT06084234Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Mass General Cancer Center, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06915753Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- Massachusetts General Hospital, Boston
被験者募集中第2相
18歳〜100歳 · 全性別 · 2026/09/23更新 · NCT07219459Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- Mass General Brigham, Boston
被験者募集中観察研究
22歳以上 · 全性別 · 2026/09/11更新 · NCT06486454Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT07166406First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Research Site, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/13更新 · NCT06795022A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston
被験者募集中第1/2相
1歳〜21歳 · 全性別 · 2026/07/06更新 · NCT04634357Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
被験者募集中
18歳〜75歳 · 全性別 · 2026/06/17更新 · NCT05486572A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
16歳以上 · 全性別 · 2026/06/02更新 · NCT07197554Computer Guided Microwave Liver Ablation
- Massachusetts General Hospital, Boston
被験者募集中
18歳〜90歳 · 全性別 · 2026/05/11更新 · NCT07226869Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
- Children's Hospital Boston, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
0歳〜30歳 · 全性別 · 2026/02/24更新 · NCT04134559Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Massachussets General Hospital, Boston
被験者募集中第4相
18歳〜64歳 · 全性別 · 2026/01/22更新 · NCT04373564SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2025/09/26更新 · NCT06265272Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
- Massachusetts General Hospital, Boston
被験者募集中
18歳以上 · 全性別 · 2025/08/29更新 · NCT06541990ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。